Risk of active tuberculosis in patients with cancer: a systematic review and metaanalysis

MP Cheng, CNA Chakra, CP Yansouni… - Clinical Infectious …, 2017 - academic.oup.com
Background. Cancer is a known risk factor for develo** active tuberculosis. We
determined the incidence and relative risk of active tuberculosis in cancer patients …

Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan

A Galaup, A Paci - Expert opinion on drug metabolism & toxicology, 2013 - Taylor & Francis
Introduction: Among the dimethanesulfonates, busulfan, in combination with other alkylating
agents or nucleoside analogues, is the cornerstone of high-dose chemotherapy. It is used …

Cost of treatment of multiple myeloma in a public sector tertiary care hospital of North India

G Kaur, S Prinja, P Malhotra, DP Lad… - Indian Journal of …, 2018 - Springer
Multiple myeloma (MM) is a neoplastic disorder, which accounts for 13% of all hematological
malignancies globally. While, conventional chemotherapy used to be the mainstay treatment …

Recent advances in the mangement of multiple myeloma.

L Kumar, P Vikram, V Kochupillai - The National Medical Journal of …, 2006 - europepmc.org
The management of multiple myeloma has undergone a major change during the past
decade. Currently, patients< 65 years of age with advanced disease (stage II-III) are best …

Consensus in the management of multiple myeloma in India at myeloma state of the art 2016 conference

U Yanamandra, N Khattry, S Kumar, N Raje… - Indian Journal of …, 2017 - Springer
The science of multiple myeloma (MM) and related plasma cell disorders is rapidly evolving
with increased understanding of the disease biology and recent approval of the newer drugs …

High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a develo** country

L Kumar, J Ghosh, P Ganessan, A Gupta… - Bone marrow …, 2009 - nature.com
We analyzed the results of 108 patients (78 males and 30 females) with multiple myeloma
who underwent autologous stem cell transplantation (ASCT). The median age of patients …

Factors affecting outcome of patients with multiple myeloma

A Basit, N Siddiqui, A Hameed… - Journal of Ayub …, 2014 - jamc.ayubmed.edu.pk
Background: Multiple myeloma is a heterogeneous disease, with wide survival range and
multiple risk factors and staging systems linked to survival. The objective of this study was to …

Haematopoietic stem cell transplantation: current status.

L Kumar - The National Medical Journal of India, 2007 - europepmc.org
Haematopoietic stem cell transplantation (HSCT) is now an established treatment fora
number of non-malignant and malignant conditions. Bone marrow-or peripheral blood …

Head and neck manifestations of myeloma in Nigerians

F Owotade, V Ugboko, S Ajike, L Salawu… - International journal of …, 2005 - Elsevier
A study on the clinicopathologic features of myeloma as it manifests in the head and neck
region was conducted over a 15-year period. A total of six patients were seen and they …

Hematological practice in India

R Das, J Ahluwalia… - Hematology/Oncology …, 2016 - hemonc.theclinics.com
Hematological practice ranges from availability of advanced diagnostic facilities and
treatment to unavailability of basic medical services to rural India. Problems include a huge …